Phase II trial of curcumin in patients with advanced pancreatic cancer

Clinical Cancer Research

Volumn 14, Issue 14, 2008, Pages 4491-4499

  Dhillon, Navneet ^a   Aggarwal, Bharat B ^b   Newman, Robert A ^b   Wolff, Robert A ^c   Kunnumakkara, Ajaikumar B ^b   Abbruzzese, James L ^c   Ng, Chaan S ^d   Badmaev, Vladimir ^e   Kurzrock, Razelle ^a,d  

^a Phase I Program   (United States)

^b Department of Experimental Therapeutics ^*

^c Division of Cancer Medicine   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e SABINSA CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; CYCLOOXYGENASE 2; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; ANTINEOPLASTIC AGENT; CYTOKINE;

ABSENCE OF SIDE EFFECTS; ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOWN REGULATION; DRUG ABSORPTION; DRUG TOLERABILITY; HUMAN; HUMAN TISSUE; PANCREAS CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; ADENOCARCINOMA; BLOOD; DRUG EFFECT; FEMALE; GEL MOBILITY SHIFT ASSAY; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; PANCREAS TUMOR;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; CURCUMIN; CYCLOOXYGENASE 2; CYTOKINES; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NF-KAPPA B; PANCREATIC NEOPLASMS;

EID: 51649118928     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0024     Document Type: Article

References (38)

1. Mancuso A, Calabro F, Sternberg CN. Current therapies and advances in the treatment of pancreatic cancer. Crit Rev Oncol Hematol 2006;58:231-41.
2. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2005;25:1960-6.
3. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-13.
4. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999; 5:119-27.
5. Aggarwal BB. Nuclear factor-κB: the enemy within. Cancer Cell 2004;6:203-8.
6. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 1999;59:4356-62.
7. Tucker ON, Dannenberg AJ. Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999;59:987-90.
8. Yip-Schneider MT, Barnard DS, Billings SD, et al. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 2000;21:139-46.
9. Singh S, Aggarwal BB. Activation of transcription factor NF-k B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem1995;270:24995-5000.
10. Anto RJ, Mukhopadhyay A, Denning K, Aggarwal BB. Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis 2002;23:143-50.
11. Aggarwal S, Ichikawa H. Takada Y, Sandur SK, Shishodia S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IκBα kinase and Akt activation. Mol Pharmacol 2006;69:195-206.
12. Li L, Aggarwal BB, Shishodia S, Abbruzzese J, Kurzrock R. Nuclear factorκ B and IκB kinase are constitutively active in human pancreatic cells, and their downregulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 2004;101:2351-62.
13. Li L, Braiteh FS, Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 2005;104:1322-31.
14. Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004;10: 6847-54.
15. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001;21;2895-900.
16. Sharma RA, McLelland HR, Hill KA, et al. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 2001;7:1894-900.
17. Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH. The use of nitrogen mustards in the palliative treatment of cancer. With particular reference to bronchogenic carcinoma. Cancer1948;1:634-56.
18. NCI-CTC Expanded Common Toxicity Criteria, Version 3.0. Available from: http://ctep.cancer.gov/forms/CTCAEv3.pdf.
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
20. Ebrahimi B, Tucker SL, Li D, Abbruzzese JL, Kurzrock R. Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer 2004;101:2727-36.
21. Chaturvedi MM, Mukhopadhyay A, Aggarwal BB. Assay for redox-sensitive transcription factor. Methods Enzymol 2000;319:585-602.
22. Bharti AC, Donato N, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive and IL-6- inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 2003;171:3863-71.
23. Lao CD, Ruffin MT IV, Normolle D, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 2006;6:10.
24. Asai A, Miyazawa T Occurrence of orally administered curcuminoid as glucuronide and glucuronide/sulfate conjugates in rat plasma. Life Sci 2000;67: 2785-93.
25. Liptay S, Weber CK, Ludwig L, Wagner M, Adler G, Schmid RM. Mitogenic and antiapoptotic role of constitutive NF-κB/Rel activity in pancreatic cancer. Int J Cancer 2003;105:735-46.
26. Xiong HQ, Abbruzzese JL, Lin E. Wang L, Zheng L, Xie K. NF-κB activity blockade impairs the angiogenic potential of human pancreatic cancer cells. Int J Cancer 2004;108:181-8.
27. Aggarwal BB, Sethi G, Ahn KS, et al. Targeting signal-transducer-and- activator-of-transcription-3 for prevention and therapy of cancer. Ann N Y Acad Sci 2006;1091:151-69.
28. Sharma RA, Gescher AJ, Steward WP Curcumin: the story so far. Eur J Cancer 2005;41:1955-68.
29. Maheshwari RK, Singh AK, Gaddipati J, Srimal RC. Multiple biological activities of curcumin: a short review. Life Sci 2006;78:2081-7.
30. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006;71:1397-421.
31. Real PJ, Sierra A, De Juan A, Segovia JC, Lopez-Vega JM, Fernandez-Luna JL. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 2002;21: 7611-8.
32. 2 production. Cancer Res 2001;61:1058-64.
33. Perkins S. Verschoyle RD, Hill K, et al. Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev 2002; 11:535-40.
34. Limtrakul P, Anuchapreeda S, Buddhasukh D. Modulation of human multidrug-resistance MDR-1 gene by natural curcuminoids. BMC Cancer 2004;4:13.
35. Jeong GS, Oh GS, Pae HO, et al. Comparative effects of curcuminoids on endothelial heme oxygenase-1 expression: ortho-methoxy groups are essential to enhance heme oxygenase activity and protection. Exp Mol Med 2006;38:393-400.
36. Ramsewak RS, DeWitt DL, Nair MG. Cytotoxicity, antioxidant and anti-inflammatory activities of curcumins l-lll from Curcuma longa. Phytomedicine 2000; 7:303-8.
37. Ahsan H, Parveen N, Khan NU, Hadi SM. Prooxidant, anti-oxidant and cleavage activities on DNA of curcumin and its derivatives demethoxycurcumin and bisdemethoxycurcumin. Chem Biol Interact 1999; 121:161-75.
38. Huang MT, Ma W, Lu YP, et al. Effects of curcumin, demethoxycurcumin, bisdemethoxycurcumin and tetrahydrocurcumin on 12-O-tetradecanoylphorbol- 13-acetate-induced tumor promotion. Carcinogenesis 1995;16:2493-7.